Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on RXI PHARMACEUTICALS. We currently have 4 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
Expanding into immuno-oncology
25 Oct 16
RXi recently announced that it has entered into an exclusive option agreement to acquire MirImmune, an early-stage private company focusing on immune checkpoint modulation, in exchange for a share amount equal to 19.99% of RXi’s outstanding stock plus milestones. MirImmune had previously licensed RXi’s sd-rxRNA technology in March 2015 and has since selected six lead compounds, which will be used alone or in combination to develop cell therapy to treat cancer. The first cell therapy will likely reach the clinic in 2018. RXi also announced a planned capital raise. If unable to raise capital, its cash runway extends only into Q217.
Samcyprone data at AAD
03 Aug 16
At the American Academy of Dermatology (AAD) Summer Meeting, data from a pilot study of Samcyprone (diphenylcyclopropenone ointment) in the treatment of common warts was presented. Overall, 38.1% of subjects saw a greater than 50% clearance over seven weeks compared to 6.7% in the placebo arm (p=0.051). On a per-protocol basis, 47.6% saw greater than 50% clearance (p=0.011). A Phase IIa with an improved formulation and 10-week treatment period was initiated in December 2015, with enrolment expected to be completed by year-end 2016.
Spotlight on cosmetic product development
18 Apr 16
RXi Pharmaceuticals (RXi) continues to make solid progress with its development pipeline. We anticipate one of two promising cosmeceutical candidates to enter human testing this year, moving forward on an expedited pathway for potential launch in 2019. We also expect data in H216 in all lead projects including RXI-109 in dermal scarring and in retinal scarring in wet AMD, and Samcyprone in cutaneous warts.
Delivering on its self-delivering RNAi platform
03 Nov 15
Over the past year, RXi Pharmaceuticals (RXi) has made significant headway with its pipeline as well as in securing partnerships. Its lead compound RXI-109 is in Phase II in dermatological scarring and is entering the clinic this year in retinal scarring in wet AMD. Phase II dermatology treatment Samcyprone was in-licensed, while a deal was struck with MirImmune for the out-licensing of its proprietary sd-rxRNA technology. We expect the company’s budding pipeline, recently simplified shareholder structure and deal-oriented strategy will continue to garner renewed investor attention and share price momentum. We value RXi at $91m or $1.40 per share.
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced
Interim results – adhering to international growth strategy
23 Feb 17
Interim results showed a strong performance for Tristel, 6% ahead of its AGM statement on 12 December at which it indicated adjusted pre-tax profits to be no less than £1.6m. Revenues increased by 22% (16% at constant exchange rates – CER or 12% CER excluding the impact of the Australian acquisition) and adjusted pre-tax profits were up 15% to £1.71m. Despite the strong half, we leave our full-year forecasts unchanged, given FX uncertainty and a one-off stocking order in H1 from the NHS, although at current FX rates the risk to our forecasts is considered to be to the upside. However, we raise our target price by 10% to 165p to reflect the solid progress as well as rolling forward our multiples to calendar-adjusted 2017.
N+1 Singer - Morning Song 21-02-2017
21 Feb 17
Abzena (ABZA LN) Contract bookings strong; US costs higher than expected | City of London Investment Group (CLIG LN) Earnings and interim dividend in line, some modest growth in FuM | dotdigital Group (DOTD LN) Good H1; broadening avenues of growth | Grafenia (GRA LN) Weak print volumes | Vernalis (VER LN) Interims highlight increasing Tuzistra™ scrip volume
Panmure Morning Note 15-02-2017
15 Feb 17
With the early January trading update having prompted us to upgrade forecasts, today’s interim results show how the group’s focus on areas such as product development and international sales are translating through to growth in both the top and bottom-line. The consistency of delivery is what impresses us, reflecting the maturity of the management team and the clarity of the longterm vision. We repeat our Buy recommendation.
N+1 Singer - Morning Song 23-02-2017
23 Feb 17
Genus (GNS LN) Interim results: R&D step-up, disappointing ABS performance | Howden Joinery Group (HWDN LN) Prelims and net cash better than expected but conditions weaken | Oxford Pharmascience Group (OXP LN) Encouraging interim OXPzero™ Ibuprofen exploratory PK data | StatPro Group (SOG LN) Increased majority shareholding in Infovest Consulting | Wilmington Group (WIL LN) Interims slightly ahead, move to focus on 3 verticals
13 Dec 16
Tristel has announced in its AGM statement that it expects to report first half adjusted (share-based payments) pre-tax profits to be no less than £1.6m. This compares with £1.5m in the 6 months to December 2015 and is in line with management’s expectations and stated strategic financial goals: (i) revenue growth within a range of 10% to 15% as an annual average over the 2016-19 period, (ii) maintaining a minimum pre-tax profit margin of 17.5% and (iii) distributing cash that is not required for the operational and investment needs of the business to shareholders in the form of dividends. Our forecasts for the full year are for adjusted pre-tax profits of £3.6m, and include a contribution from the acquisition of its previous Australian distributor for its Wipes System from 21 July 2016 (ie 11 months contribution in the full year). Our forecasts also include £0.5m of US development expenses for the full year (incremental £370k), which impacts margins by c190bps. We make no changes to either our forecast or target price; however, note that risks to both of these are on the upside.